A phase I trial of AVN-944 in patients with advanced hematologic malignancies

Trial Profile

A phase I trial of AVN-944 in patients with advanced hematologic malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2011

At a glance

  • Drugs AVN 944 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Avalon Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
    • 09 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2008 The company is on track to complete this trial in 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top